A case of pancreatic cancer after heart transplantation.
Malignancy is not uncommon with immunosuppressive therapy, but pancreatic cancer is infrequently complicated in recipients of heart transplantation. Here we report a transplant case diagnosed with pancreatic cancer 4 years and 8 months after the heart transplantation. We changed the immunosuppressive regimen after the malignancy was detected, and administered everolimus along with chemotherapy using S-1, an oral fluoropyrimidine prodrug. The patient lived for 8 months after the diagnosis, and received metallic stenting for the biliary and duodenal obstruction. Also, to the best of our knowledge, this is the first report about chemotherapy and endoscopic intervention for pancreatic cancer in a heart transplantation patient.
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Teruhiko
T
Imamura
Koichiro
K
Kinugawa
Dai
D
Mohri
Taro
T
Shiga
Miyoko
M
Endo
Toshiro
T
Inaba
Hisataka
H
Maki
Masaru
M
Hatano
Hiroyuki
H
Isayama
Atsushi
A
Yao
Yasunobu
Y
Hirata
Kazuhiko
K
Koike
Ryozo
R
Nagai
D000230:Adenocarcinoma / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D001651:Cholestasis, Extrahepatic / Q000175:diagnosis / Q000628:therapy; D003131:Combined Modality Therapy; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004380:Duodenal Obstruction / Q000175:diagnosis / Q000628:therapy; D000068338:Everolimus; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000601:surgery*; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D011183:Postoperative Complications / Q000175:diagnosis* / Q000628:therapy; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015607:Stents; D005641:Tegafur / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D007166:Immunosuppressive Agents; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000068338:Everolimus; D020123:Sirolimus